- AdventHealth
AdventHealth Central Florida conducted a pilot program called Mother’s Heart Wise to identify women with adverse pregnancy outcomes that increase their lifetime risk of developing cardiovascular (CV) disease and connect them to an ongoing, preventive care plan that reduces that risk.
Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia), gestational diabetes mellitus (DM), intrauterine growth restriction/small for gestational age (IUGR/SGA), and pre-term delivery have all been identified as atherosclerotic cardiovascular disease (ASCVD) risk factors for women. Specific findings include the following:
- A history of preeclampsia or gestational hypertension doubles a woman’s lifetime risk of ischemic cardiac disease or stroke.
- Women with gestational diabetes mellitus have a twofold higher risk of cardiovascular events. This risk is not dependent upon the development of type 2 diabetes and is apparent within the first decade postpartum.
The American Heart Association and the American College of Obstetricians and Gynecologists issued a joint advisory in 2018 that focused on how obstetricians can help optimize women’s CV health through early identification and modification of risk factors. The report emphasized that despite heart disease being the number one killer of women, only 45% of women identify it as such. In addition, a multinational cohort study published earlier this year in the American Journal of Obstetrics & Gynecology found that better CV health at 24-32 weeks gestation was associated with lower risks for severe adverse maternal and newborn outcomes.
Under the leadership of Cardiologist Patricia Guerrero, MD, and OB/GYN D. Ashley Hill, MD, and in collaboration with Family Physician Christopher Buelvas, MD, AdventHealth has developed and is piloting Mother’s Heart Wise to achieve the following:
- Proactively identify patients within the health system who have adverse pregnancy disorders and outcomes
- Educate them about their risk factors
- Get them into a proactive care plan
- Improve their long-term CV health
“Each year, our Central Florida Division performs over 16,000 deliveries and sees approximately 6,500 women with one or more adverse pregnancy outcomes that increase their risk for cardiovascular disease,” explains Dr. Hill. “This doesn’t even include women identified during annual well women visits. Because of the size and integration of our system, we saw this as a tremendous opportunity to work in a coordinated, multidisciplinary fashion to intervene early and positively impact the life-long cardiovascular health of our patients.”
Care Coordination — Women’s Health Nurse Navigator
Through this pilot project, AdventHealth OB/GYN teams have initially identified 40 at-risk women who have been referred to a women’s health nurse navigator at 6 weeks postpartum to coordinate their long-term follow-up care. This includes assistance with the following:
- Finding a primary care provider (PCP)
- Answering health care questions
- Assisting with scheduling office visits and screenings
- Providing resources and support to help with adopting healthy habits, such as exercising daily, eating a heart healthy diet and maintaining a healthy weight
Physician Care Pathways
In addition, to coordinate patient care amongst the OB/GYNs and primary care providers, the following two initial physician care pathways have been established:
Hypertensive Disorders of Pregnancy
- Pregnancy and Early Postpartum Management:
- OB/GYN addresses patient education and home blood pressure (BP) monitoring
- Referral at 6 weeks postpartum to PCP for Cardiovascular Risk Reduction (via women’s health nurse navigator)
- Inter-pregnancy Management:
- PCP visit timing based on BP at 6-week visit
- Within 1-2 months if the patient is normotensive at 6 week postpartum
- Accelerated PCP visit within 1-2 weeks if persistent hypertension or additional CV risks
- PCP Visit:
- Documentation of gestational hypertension (HTN)
- Patient education regarding increased risk (lifetime risk)
- Screen for CV risk factors
- Additional testing, including creatinine, metabolic panel and ECG
- Counsel and refer to ancillary services
- Home BP monitoring
- Manage CV risks
- Reevaluate at regular intervals
Gestational Diabetes Mellitus
- Pregnancy and Early Postpartum Management:
- OB/GYN tests for undiagnosed DM or pre-DM during pregnancy
- Oral glucose tolerance test (OGTT) or fasting glucose performed at 6 weeks postpartum.
- Referral at 6 weeks postpartum to PCP for cardiovascular risk reduction (via women’s health nurse navigator)
- Inter-pregnancy and Long-term Management:
- Primary care physician
- PCP Visit:
- Documentation of gestational DM
- Patient education regarding increased risk of CV events (lifetime risk) and development of DM
- Additional testing, including OGTT or fasting blood sugar at 4-12 weeks postpartum if not already performed
- Life-long screening with OGTT or HbA1c for those without manifest diabetes every 1-3 years
- Screen and manage CV risk factors
- Intensive lifestyle intervention and/or metformin to prevent DM
The Mother’s Heart Wise team has also developed an intake questionnaire that physicians can use to identify women within their practices who are at increased CV risk due to adverse pregnancy outcomes.
(Insert Box/Graphic)
Patient Intake Questionnaire to Identify Women at Higher Risk for Cardiovascular Disease Due to Adverse Pregnancy Outcomes
- How many pregnancies have you had?
- Were any of your babies born early (more than three weeks before your due date)?
- How many?
- Did this occur spontaneously or were you delivered early because you were ill?
- Did you have preeclampsia in any of your pregnancies?
- Which pregnancy?
- How many times?
- Were you delivered early because you had preeclampsia?
- How many weeks before your due date were you delivered?
- Did you have high blood pressure in any pregnancy?
- Did you have protein in your urine that pregnancy?
- Did you have hypertension after that pregnancy?
- What was the weight of your babies and how many weeks before your due date were they delivered?
- Did you have gestational diabetes during your pregnancies?
Looking Ahead
Drs. Hill, Guerrero and their team hope to complete the initial phase of the pilot project this summer and then make adjustments to the Mother’s Heart Wise program as needed based on any barriers identified as well as feedback from the patients and providers. Anticipated benefits of the program include improved CV outcomes in women with adverse outcomes of pregnancy, reduced lifelong healthcare costs and improved patient satisfaction.
“As physicians, our ultimate goal is to positively impact the health of our patients,” he said. “We believe by better identifying, educating and addressing the long-term risks posed by adverse pregnancy outcomes, we can do just that.”
For more information about the Mother’s Heart Wise project, contact the AdventHealth Women’s Health Nurse Navigator at Call407-720-5191.
About D. Ashley Hill, MD:
Ashley Hill, MD, is a Medical Director of obstetrics and gynecology at AdventHealth Medical Group and Associate Director of the AdventHealth Graduate Medical Education Program’s Department of Obstetrics and Gynecology. Additionally, Dr. Hill is a Professor of Obstetrics and Gynecology at the UCF College of Medicine. He received his medical degree from the University of South Florida College of Medicine, where he also completed his residency. Dr. Hill specializes in abnormal uterine bleeding, treatment of uterine fibroids, minimally invasive gynecologic surgery, normal and high-risk pregnancies, and ultrasonography. He has published numerous papers in medical journals, serves as an expert reviewer for several journals, and is the Medical Director of the Multiprofessional Obstetric Simulation Training (MOST®) program and the Women’s and Children’s Quality Improvement Committee. Dr. Hill is board certified by The American Board of Obstetrics and Gynecology.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...